X4 Pharmaceuticals (XFOR) Other Non Operating Income (2017 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly Other Non Operating Income came in at -$676000.0 in Q3 2025, down 399.12% YoY from $226000.0 in Q3 2024, and down 125.59% on a QoQ basis from $2.6 million in Q2 2025.
X4 Pharmaceuticals (XFOR) Other Non Operating Income (2017 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of Other Non Operating Income data on file, last reported at -$676000.0 in Q3 2025.
- Quarterly Other Non Operating Income fell 399.12% year-over-year to -$676000.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $12.8 million (up 1031.39% YoY) and the FY2025 annual result came in at $12.8 million, up 3748.8% from the prior year.
- Other Non Operating Income retreated to -$676000.0 in Q3 2025, from $2.6 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $10.8 million in Q1 2025 to a low of -$676000.0 in Q3 2025.
- A 5-year average of $1.2 million and a median of $123000.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income tumbled 495.95% — and 2025, when it soared 10214.29%.
- Tracing XFOR's Other Non Operating Income over 5 years: stood at $103000.0 in 2021, then surged by 1978.64% to $2.1 million in 2022, then jumped by 214.43% to $6.7 million in 2023, then tumbled by 89.6% to $700000.0 in 2024, then plunged by 196.57% to -$676000.0 in 2025.
- The last three Other Non Operating Income figures came in at -$676000.0 (Q3 2025), $2.6 million (Q2 2025), and $10.8 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 528,000.00 |
| Sep 30, 2025 | -676,000.00 |
| Jun 30, 2025 | 2.64 Mn |
| Mar 31, 2025 | 10.83 Mn |
| Dec 31, 2024 | 700,000.00 |
| Sep 30, 2024 | 226,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 105,000.00 |
| Dec 31, 2023 | 6.73 Mn |
| Sep 30, 2023 | 17,000.00 |
| Jun 30, 2023 | 202,000.00 |
| Mar 31, 2023 | 123,000.00 |
| Dec 31, 2022 | 2.14 Mn |
| Sep 30, 2022 | -441,000.00 |
| Jun 30, 2022 | -59,000.00 |
| Mar 31, 2022 | 60,000.00 |
| Dec 31, 2021 | 103,000.00 |
| Sep 30, 2021 | -74,000.00 |
| Jun 30, 2021 | 210,000.00 |
| Mar 31, 2021 | 186,000.00 |